NGM Bio sub­ject of take-pri­vate bid by in­sti­tu­tion­al in­vestor The Col­umn Group

NGM Bio, with a spate of clin­i­cal set­backs and fi­nan­cial woes in re­cent years, has re­ceived an un­so­licit­ed ac­qui­si­tion bid from share­hold­er The Col­umn Group …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER